Zobrazeno 1 - 6
of 6
pro vyhledávání: ''
Publikováno v:
Cancer Investigation. 38:549-558
To evaluate prognosis of breast cancer patients, a total of 16,618 TNBC patients from SEER database were involved. High grade, unmarried status, tumor site were the main factors reduced OS in stage I. Black race, unmarried, large tumor size, and node
Publikováno v:
Cancer Investigation. 29:365-369
p53 and HER-2 coexpression in breast cancer has been controversial. These markers were tested using immunohistochemistry and HercepTest. HER-2 expression is related to reduced breast cancer survival (p = .02) . p53 expression relates to HER-2 express
Publikováno v:
Cancer Investigation. 17:181-188
Advanced metastatic non-small cell lung cancer (NSCLC) that has progressed on initial cisplatin-based chemotherapy has a poor prognosis. Although paclitaxel is an active agent in the first-line therapy of NSCLC, 24-hr infusion of paclitaxel in patien
Autor:
Sue Anne Sullivan, Frederic H. Kass, George W. Comstock, Sharon Eby, Marianna Zahurak, Richard M. Smith, John H. Fetting, A M Huelskamp, Jonathan M. Gerber
Publikováno v:
Cancer Investigation. 15:199-203
Older women (i.e.,or = 65 years of age) receive less adjuvant chemotherapy than younger women, in part because chemotherapy has been less effective in postmenopausal than premenopausal women in clinical trials. Metastatic breast cancer, however, does
Autor:
Philippe Chollet, Catherine Abrial, C. Pomel, Emilie Thivat, Marie-Ange Mouret-Reynier, Jean-Marc Nabholtz, Fabrice Kwiatkowski, Jean-Pierre Ferriere, Eloise Planchat, Xavier Durando
Publikováno v:
Cancer investigation. 29(9)
Classical prognostic factors of breast cancer are correlated to disease-free survival and overall survival (OS); their precise role is less known on metastatic disease. A total of 511 breast cancer patients without initial metastasis were treated. OS
Autor:
Mustafa Erman, Gülten Tekuzman, Iskender Sayek, Hüseyin Engin, Nilüfer Güler, Esmen Baltali, Kadri Altundag, Demirali Onat, I. Lale Atahan, Yavuz Ozisik, Huseyin Abali, Aziz Karaoglu
Publikováno v:
Cancer investigation. 23(3)
The incorporation of a taxane into an anthracycline-containing regimen in the adjuvant treatment of breast cancer is a promising approach. In this study, we aimed to evaluate the safety and efficacy of four cycles of FEC (fluorouracil 500 mg/m(2), ep